Literature DB >> 32078161

Direct visual targeting versus preset coordinates for ANT-DBS in epilepsy.

Terje Nome1, Helle Herrman2,3,4, Kai Lehtimäki5, Arild Egge6, Ane Konglund6, Jon Ramm-Pettersen6, Erik Taubøll2,4, Espen Dietrichs2,4.   

Abstract

OBJECTIVES: Deep brain stimulation (DBS) of the anterior thalamic nucleus (ANT) may be used against refractory focal epilepsy, but only two randomized double-blinded trials have been performed. The Oslo study was discontinued prematurely since reduction in seizure frequency was less than expected. The aim of the present study was to review the targeting used in the Oslo study and to identify the actual positions of the contacts used for stimulation.
MATERIAL AND METHODS: BrainLab MRI data were available from 12 Oslo study patients. Based on MRI the coordinates of the center of the ANT were identified. The coordinates were considered as the visually identified preferred target and were compared with the target originally used for ANT electrode implantation and with the actual electrode positions estimated from post-operative CT scans.
RESULTS: We found considerable differences between the visually identified preferred target, the originally planned target, and the actual electrode position. The total distance between the active electrode position and the visually identified preferred target was on average 3.3 mm on the right and 2.9 mm on the left side.
CONCLUSION: Indirect targeting based on preset coordinates may contribute to explain the modest effect of ANT-DBS on seizure frequency seen in the Oslo study. Observed differences between the center of the ANT and the actual electrode position may at least in part be explained by variations in position and size of the ANT. Direct identification of the target using better MRI imaging protocols is recommended for future ANT-DBS surgery.
© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.

Entities:  

Keywords:  anterior nucleus of thalamus; deep brain stimulation; epilepsy

Year:  2020        PMID: 32078161     DOI: 10.1111/ane.13233

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  1 in total

1.  ANT-DBS in epilepsy shows no effect on selected neuropsychiatric tests.

Authors:  Helle Herrman; Kåre Osnes; Arild Egge; Ane Konglund; Jon Ramm-Pettersen; Espen Dietrichs; Erik Taubøll
Journal:  Acta Neurol Scand       Date:  2022-06-01       Impact factor: 3.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.